Drugs / AlloRx Stem Cells®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05165017 Comparator | Dec 2021 → Dec 2022 | Pitt-Hopkins syndrome | Vitro Biopharma Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloRx stem cells | “This is a phase 1/2, randomized placebo controlled double blinded standard dose study to evaluate the safety and tolerability of AlloRx® stem cells in pediatric patients with a...” NCT05165017 ↗ |
| Modality | Cell therapy | “Umbilical cord-derived allogeneic mesenchymal stem cells” NCT05165017 ↗ |
| Route | Intravenous | “intravenous administration” NCT05165017 ↗ |